Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Memorial Hermann
mi
from
Houston, TX
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Memorial Hermann
mi
from
Houston, TX
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Virginia Commonwealth
mi
from
Richmond, VA
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Virginia Commonwealth
mi
from
Richmond, VA
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Froedtert East Hospital
mi
from
Milwaukee, WI
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Froedtert East Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
University of Arizona Medical Center
mi
from
Tuscon, AZ
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
University of Arizona Medical Center
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Stanford Medical Center
mi
from
Palo Alto, CA
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Stanford Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Hennepin County Medical Center
mi
from
Minneapolis, MN
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated:  12/16/2015
Brooke Army Medical Center
mi
from
San Antonio, TX
Progesterone for the Treatment of Traumatic Brain Injury III
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Status: Enrolling
Updated: 12/16/2015
Brooke Army Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pain Assessment in the Intensive Care Unit
Pain Assessment in the Intensive Care Unit
Status: Enrolling
Updated:  12/16/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Pain Assessment in the Intensive Care Unit
Pain Assessment in the Intensive Care Unit
Status: Enrolling
Updated: 12/16/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
Bethesda North Hospital
mi
from
Cincinnati, OH
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
Bethesda North Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
Good Samaritan Hospital
mi
from
Cincinnati, OH
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
Good Samaritan Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
Jewish Hospital
mi
from
Cincinnati, OH
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
Jewish Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
St. Elizabeth Healthcare Florence
mi
from
Florence, KY
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
St. Elizabeth Healthcare Florence
mi
from
Florence, KY
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
St. Elizabeth Healthcare Ft. Thomas
mi
from
Ft. Thomas, KY
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
St. Elizabeth Healthcare Ft. Thomas
mi
from
Ft. Thomas, KY
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
St. Elizabeth Healthcare System Edgewood
mi
from
Edgewood, KY
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
St. Elizabeth Healthcare System Edgewood
mi
from
Edgewood, KY
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
The Christ Hospital
mi
from
Cincinnati, OH
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated:  12/16/2015
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)
Status: Enrolling
Updated: 12/16/2015
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Primary Care Stepping Stones Triple P for Children With Autism
A Pilot Study of Primary Care Stepping Stones Triple P for Children With Autism
Status: Enrolling
Updated:  12/16/2015
Saint Louis University, Knights of Columbus Developmental Center
mi
from
St. Louis, MO
Primary Care Stepping Stones Triple P for Children With Autism
A Pilot Study of Primary Care Stepping Stones Triple P for Children With Autism
Status: Enrolling
Updated: 12/16/2015
Saint Louis University, Knights of Columbus Developmental Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated:  12/16/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated: 12/16/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated:  12/16/2015
New York State Psychiatric Institute
mi
from
New York, NY
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated: 12/16/2015
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated:  12/16/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Pharmacological Treatment of ADHD in Young Children
Status: Enrolling
Updated: 12/16/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Comparison of 2 Vials of Components of a Synthetic Geranium Oil
EPT 101: New Geranium Oil Formulation for the Treatment of Neuropathy Pain
Status: Enrolling
Updated:  12/17/2015
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Comparison of 2 Vials of Components of a Synthetic Geranium Oil
EPT 101: New Geranium Oil Formulation for the Treatment of Neuropathy Pain
Status: Enrolling
Updated: 12/17/2015
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
Status: Enrolling
Updated:  12/17/2015
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
Status: Enrolling
Updated: 12/17/2015
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Geranium Oil and Its Components for the Relief of Numbness-OB 100
Geranium Oil and Its Components for the Relief of Numbness-OB 100
Status: Enrolling
Updated:  12/17/2015
Penningto Biomedical Research Center
mi
from
Baton Rouge, LA
Geranium Oil and Its Components for the Relief of Numbness-OB 100
Geranium Oil and Its Components for the Relief of Numbness-OB 100
Status: Enrolling
Updated: 12/17/2015
Penningto Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population
Status: Enrolling
Updated:  12/17/2015
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population
Status: Enrolling
Updated: 12/17/2015
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population
Attention Deficit/Hyperactivity Disorder (ADHD) Internet Survey Study in a College Student Population
Status: Enrolling
Updated:  12/17/2015
Wake Forest University Health Sciences
mi
from
Winston Salem, NC
Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population
Attention Deficit/Hyperactivity Disorder (ADHD) Internet Survey Study in a College Student Population
Status: Enrolling
Updated: 12/17/2015
Wake Forest University Health Sciences
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Chicago, IL
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Birmingham, AL
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Little Rock, AR
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
San Diego, CA
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Newark, DE
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Washington,
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Atlanta, GA
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Honolulu, HI
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Louisville, KY
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Baltimore, MD
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Ayer, MA
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Ayer, MA
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Detroit, MI
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Duluth, MN
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
St Louis, MO
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Kalispell, MT
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Kalispell, MT
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Bronx, NY
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Asheville, NC
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Akron, OH
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Bend, OR
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Anderson, SC
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Anderson, SC
Click here to add this to my saved trials
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Houston, TX
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials